#1LEADING ANIMAL HEALTH ACROSS THE CONTINUUM OF CARE 9-28 22 9Z zoetis#227 2 MANUFACTURING SITES !!! APPROXIMATE R&D COLLEAGUES 1,100 zgets 8 $6.3 CORE ANIMAL SPECIES BILLION ANNUAL REVENUE MAJOR PRODUCT CATEGORIES hassa 300 WE PROVIDE MEDICINES VACCINES DIAGNOSTICS 7 MARKET PRESENCE IN 100+ 10,600 APPROXIMATE COLLEAGUES WORLDWIDE APPROXIMATE NUMBER OF PRODUCT LINES GENETIC TESTS BIODEVICES PRECISION LIVESTOCK FARMING E 65+ YEARS OF EXPERIENCE OUR FOCUS 51% 49% 3,200 COMPANION ANIMAL HEALTH LIVESTOCK APPROXIMATE HEALTH FIELD FORCE MEMBERS COUNTRIES Note: Facts and figures shown are as of Dec. 31, 2019 | ¹Excludes revenue associated with Client Supply Services, which represented 1% of total 2019 revenue. zoetis#3VISION ZOETIS VISION AND STRATEGY STRATEGIC PRIORITIES FOCUS AREAS CORE BELIEFS 3 M Drive Innovative Growth Deliver innovative products across the continuum of care Capitalize on emerging growth opportunities OUR COLLEAGUES MAKE THE DIFFERENCE ● REIMAGINING ANIMAL HEALTH Across the Continuum of Care Enhance Customer Experience Provide personalized and integrated solutions that differentiate Zoetis Make it easier and more valuable to do business with us ALWAYS DO THE RIGHT THING Lead in Digital and Data Analytics Develop new digital and data analytics solutions for customers Advance and scale internal digital and technology capabilities CUSTOMER OBSESSED 18.. Cultivate a High-performing Organization Drive operational excellence and agility Attract, develop and retain top talent with a high-performing culture RUN IT LIKE YOU OWN IT Champion a Healthier, More Sustainable Future Promote a safe and sustainable global food supply and environment Increase access to animal care globally WE ARE ONE ZOETIS zoetis#4ZOETIS: LEADING ANIMAL HEALTH ACROSS THE CONTINUUM OF CARE • Global leader in an attractive market with sustainable growth drivers and opportunities ● ● Diverse and durable portfolio with proven strength in innovation 4 Track record of delivering strong financial results and disciplined capital allocation • Clear strategic priorities to deliver continued above-market growth and long-term value $6.3B 2019 REVENUE +336% TOTAL SHAREHOLDER RETURN SINCE IPO THOUGH DEC. 31, 2019³ -300 NUMBER OF PRODUCT LINES ACROSS 8 SPECIES 10% OPERATIONAL REVENUE GROWTH 1 45 COUNTRIES WITH DIRECT PRESENCE ¹ Operational revenue growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. 2 Total Shareholder Return (TSR) represents the total return between 2/1/13 (first day of ZTS trading) and 12/31/19; if the IPO date of 1/31/13 were used, TSR would be 420%. Calculation does not include reinvestment of dividends. 1,100+ NEW PRODUCTS & LIFECYCLE INNOVATIONS INTRODUCED IN THE LAST 5 YEARS zoetis#5DIVERSE, DURABLE AND INNOVATIVE PORTFOLIO DRIVEN BY CONTINUOUS PRODUCT AND LIFECYCLE INNOVATION ● ● ● ● Broad portfolio with ~300 product lines across 8 species Leading brands including 13 blockbusters¹ representing more than 1/3 of those in the industry Diversified revenue streams with top 10 products ² accounting for ~40% of total revenue Durable portfolio with average market life of top 24 product lines and products at ~29 years ³ • Continuous innovation flow with 1,100+ new products and lifecycle innovations introduced in the last 5 years 13 BLOCKBUSTERS¹ A blockbuster is a product or product line that has $100M or more in annual revenue. Blockbusters shown on this slide are as of 2019. 2 Top products each contribute at least 1% of total revenue 3 Based on 2019 sales data. Market life refers to the number of years a product has been commercially available. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. 5 apoque) CLAVAMOX™ CY TOPOINT. EXCEDE E CENEL SPECTRAMAST (Ceftiofur product line) ProHeartⓇ Simparica VETSCAN Chemistry Analyzer Cerenia convenia cefovecin sodium Draxxin Fostera.Gold SUVAXYN PCV RIMADYL® stronghold® revolution zoetis#6DURABLE AND DIVERSE PORTFOLIO PLANNING FOR A CONTINUOUS FLOW OF PRODUCTS 10+ YEARS <10 YEARS Actogain 45 CYTOPOINT. Simparica ALPHA JECT LiVac SRS ALPHA JECT microⓇ 1PD apoque) Engain Ractopamine Hydrochloride Fostera.Gold INFORCE 3 CLARIFIDE. PCV MH plus stronghold selamectin/sarolaner PLUS VERSICAN Plus VETSCAN Core EQ Innovator™ Bovi-Shield GOLD Improvac DECTOMAX. Cerenia (maropitant citrate) CLAVAMOX convenia Draxxin (tulathromycin) Injectable Solution POULVAC revolution SUVAXYN PCV RIMADYL 25+ YEARS SPECTRAMAST NAXCEL (ceftiofur sodium) Sterile Powder WITNESS™ The average age of our top 24 products is approx. 29 years ¹ VANGUARD™ Liquamycin LA-200 Zoamix 1 Based on 2019 sales data. Age refers to the number of years a product has been commercially available. Top products each contribute at least 1% of total revenue. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. 6 60+ YEARS Terramycin Powder zoetis#7OUR COMPETITIVE ADVANTAGES 7 1 Leadership in Innovation 2 Direct Access to Customers 3 High Quality Manufacturing & Supply Diverse Global Portfolio 4 5 6 7 Track Record of Execution Results-Driven Culture Financial Strength and Investment Focus zoetis#8INNOVATING ACROSS THE CONTINUUM OF CARE Data Analytics & Sensors 8 Vaccines, Robotics & Automation Genetics PREDICT PREVENT 80 Diagnostics DETECT ZOETIS CONTINUUM OF CARE TREAT Medicines zoetis#9HIGH-QUALITY PRODUCTS, DELIVERED BY OUR WORLD-CLASS MANUFACTURING OPERATIONS R EXCELLENCE IN QUALITY RELIABLE SUPPLY BREADTH OF EXPERTISE 9 COST/EFFICIENCY IMPROVEMENTS ♡ SPEED TO MARKET 1/ Charles City, IA Eagle Grove, IA Lincoln, NE City, CA Union Buellton, CA Chicago Heights, IL London, Ontario, Canada Kalamazoo, MI Willow Island, WV Durham, NC San Diego, CA Tallaght, Ireland Salisbury, MD White Hall, IL NOTE: Sites shown are as of Dec. 31, 2019 Overhalla, Norway Klofta, Norway Farum, Denmark Campinas, Brazil LLN, Belgium Olot, Spain -Weibern, Austria Medolla, Italy Catania, Italy Suzhou, China Jilin, China Melbourne, Australia Wellington, NZ zoetis#10WORLDWIDE MARKET LEADER WELL-POSITIONED TO DRIVE CONTINUED ABOVE-MARKET GROWTH¹ ACROSS ANIMAL HEALTH | BY SPECIES Companion Animal I I Cattle I Swine Fish³ Poultry 10 2019 MARKET POSITION #1 #1 #3 BY PRODUCT CATEGORY #1 Other Pharma² #1 Anti-Infectives I | Medicated Feed Additives (MFA) Vaccines (Biologicals) Parasiticides #1 #1 #2 #3 #4 BY GEOGRAPHY North America Latin America Asia Eastern Europe Western Europe Rest of World #1 #1 #2 #2 #3 #3 Market Leader in Species Representing ~90% of Our Portfolio by Revenue 4 1 Vetnosis 2020 Executive's Guide March 2020 2 Includes pain, sedation, internal medicine, dermatology etc. 3 Internal sales estimate based on distribution channels for FY 2019 zoetis 4 FY 2019